 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5515 News |  |
| «12...5859606162636465666768...6970» |
- | Perjeta (pertuzumab) / Roche
New trial: CARE-B: CARdiac Function Evaluation in Breast Cancer Patients (clinicaltrials.gov) - Aug 29, 2017
P=N/A, N=25, Recruiting, Sponsor: Swansea University
- || Perjeta (pertuzumab) / Roche
Trial completion, Combination therapy, Metastases: SAPPHIRE: A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Aug 29, 2017
P3, N=50, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed
- |||||||||| Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial, Combination therapy: EMERALD: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (clinicaltrials.gov) - Aug 29, 2017
P3, N=480, Not yet recruiting, Sponsor: Japan Breast Cancer Research Group
- | Perjeta (pertuzumab) / Roche
Journal: Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. (Pubmed Central) - Aug 23, 2017
Numerically fewer patients discontinued treatment because of adverse events in the T-DM1 arms, and health-related quality of life was maintained for longer in the T-DM1 arms. Conclusion T-DM1 showed noninferior, but not superior, efficacy and better tolerability than did taxane plus trastuzumab for first-line treatment of HER2-positive, advanced breast cancer.
- | metformin / Generic mfg.
Enrollment open: HERMET: Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer (clinicaltrials.gov) - Aug 7, 2017
P2, N=100, Recruiting, Sponsor: Qamar Khan
Conclusion T-DM1 showed noninferior, but not superior, efficacy and better tolerability than did taxane plus trastuzumab for first-line treatment of HER2-positive, advanced breast cancer. Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, Trial completion: Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer (clinicaltrials.gov) - Aug 7, 2017
P2, N=16, Completed, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | metformin / Generic mfg.
New P2 trial: HERMET: Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer (clinicaltrials.gov) - Aug 2, 2017
P2, N=100, Not yet recruiting, Sponsor: Qamar Khan
- | Review, Journal: Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. (Pubmed Central) - Jul 26, 2017
At this time, only two biologic therapies are recommended by the National Comprehensive Cancer Network (NCCN): trastuzumab for patients with esophageal/esophagogastric or gastric adenocarcinomas with HER2 overexpression and ramucirumab, a VEGFR-2 inhibitor, as a second-line therapy for metastatic disease. However, recent reports of increases in overall and progression-free survival for agents including pertuzumab, apatinib, and pembrolizumab will likely increase the use of targeted biologic therapy in clinical practice for esophageal and gastric malignancies.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, FDG PET: PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (clinicaltrials.gov) - Jul 21, 2017
P2, N=400, Recruiting, Sponsor: MedSIR
However, recent reports of increases in overall and progression-free survival for agents including pertuzumab, apatinib, and pembrolizumab will likely increase the use of targeted biologic therapy in clinical practice for esophageal and gastric malignancies. Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Metastases: PATRICIA: A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy (clinicaltrials.gov) - Jul 19, 2017
P2, N=40, Active, not recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Surgery, Metastases: PEONY: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel (clinicaltrials.gov) - Jul 18, 2017
P3, N=329, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2022 --> Dec 2017
- ||||||| Trial completion, Trial primary completion date: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) (clinicaltrials.gov) - Jul 13, 2017
P3, N=961, Completed, Sponsor: German Breast Group
Trial primary completion date: Apr 2022 --> Dec 2017 Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Nov 2016
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Jul 11, 2017
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Nov 2016 Trial primary completion date: Dec 2018 --> Dec 2019
- ganetespib (ADX-1612) / Aldeyra, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (clinicaltrials.gov) - Jul 6, 2017
P1, N=9, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Jun 2017 --> Jun 2018
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change, BRCA Biomarker: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (clinicaltrials.gov) - Jul 2, 2017
P2, N=23, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jun 2017 --> Jun 2018 Recruiting --> Active, not recruiting | N=30 --> 23
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer (clinicaltrials.gov) - Jul 2, 2017
P1/2, N=46, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting | N=30 --> 23 Trial primary completion date: Sep 2017 --> Sep 2018
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer (clinicaltrials.gov) - Jun 23, 2017
P2a, N=30, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2017 --> Sep 2018 Trial primary completion date: May 2016 --> Mar 2015
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Jun 21, 2017
P2, N=401, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2016 --> Mar 2015 Trial primary completion date: Nov 2020 --> Mar 2016
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. (Pubmed Central) - Jun 15, 2017
P3
In patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab or placebo, higher TIL values are significantly associated with improved overall survival, suggesting that the effect of antitumour immunity extends to the advanced setting. Future clinical studies in this cancer subtype should consider TILs as a stratification factor and investigate whether therapies that can augment immunity could potentially further improve survival.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Jun 14, 2017
P2, N=65, Recruiting, Sponsor: City of Hope Medical Center
Future clinical studies in this cancer subtype should consider TILs as a stratification factor and investigate whether therapies that can augment immunity could potentially further improve survival. Trial primary completion date: Aug 2017 --> Aug 2018
- |||| Trial primary completion date: KRISTINE: A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (clinicaltrials.gov) - Jun 8, 2017
P3, N=444, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2017 --> Aug 2018 Trial primary completion date: Jan 2018 --> Dec 2015
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer (clinicaltrials.gov) - Jun 8, 2017
P2a, N=50, Recruiting, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Jan 2018 --> Dec 2015 Not yet recruiting --> Recruiting
- |||||| Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date, Metastases: PATINA: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (clinicaltrials.gov) - May 31, 2017
P3, N=496, Recruiting, Sponsor: Alliance Foundation Trials, LLC.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Feb 2017 --> Jun 2017
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Phase classification, Trial primary completion date, Combination therapy: MotHER: A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine (clinicaltrials.gov) - May 31, 2017
P=N/A, N=100, Recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting | Initiation date: Feb 2017 --> Jun 2017 Phase classification: P4 --> P=N/A | Trial primary completion date: Dec 2022 --> Jan 2025
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion: TRAP: Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma (clinicaltrials.gov) - May 31, 2017
P1/2, N=40, Completed, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase classification: P4 --> P=N/A | Trial primary completion date: Dec 2022 --> Jan 2025 Recruiting --> Completed
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab (clinicaltrials.gov) - May 29, 2017
P1, N=20, Recruiting, Sponsor: University of Michigan Cancer Center
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date: BrUOG 308: Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. (clinicaltrials.gov) - May 24, 2017
P2, N=30, Recruiting, Sponsor: William Sikov
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Nov 2016
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change, Metastases: Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer (clinicaltrials.gov) - May 19, 2017
P2, N=33, Active, not recruiting, Sponsor: US Oncology Research
Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Nov 2016 Recruiting --> Active, not recruiting | N=200 --> 33
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, FDG PET: PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (clinicaltrials.gov) - May 18, 2017
P2, N=400, Not yet recruiting, Sponsor: MedSIR
- | Herceptin (trastuzumab) / Roche, Actimmune (interferon gamma-1 b) / Clinigen, Amgen, Perjeta (pertuzumab) / Roche
Enrollment open: MCC-18936: Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer (clinicaltrials.gov) - May 12, 2017
P1/2, N=43, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting | N=200 --> 33 Not yet recruiting --> Recruiting
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: JACOB: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (clinicaltrials.gov) - May 12, 2017
P3, N=780, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2021 --> Dec 2016
- | paclitaxel / Generic mfg.
Trial initiation date: ARETTA: Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer (clinicaltrials.gov) - May 9, 2017
P2, N=60, Not yet recruiting, Sponsor: University of Chicago
Trial primary completion date: Dec 2021 --> Dec 2016 Initiation date: Apr 2017 --> Nov 2017
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Surgery, Metastases: PEONY: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel (clinicaltrials.gov) - May 4, 2017
P3, N=328, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Apr 2017 --> Nov 2017 Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial primary completion date, Metastases: Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy (clinicaltrials.gov) - May 3, 2017
P2, N=45, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Sep 2018
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P1 trial, Combination therapy, Metastases: Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab (clinicaltrials.gov) - Apr 30, 2017
P1, N=20, Not yet recruiting, Sponsor: University of Michigan Cancer Center
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, BRCA Biomarker: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (clinicaltrials.gov) - Apr 28, 2017
P2, N=30, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Sep 2018 Trial primary completion date: Mar 2017 --> Jun 2018
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: APHINITY: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (clinicaltrials.gov) - Apr 21, 2017
P3, N=4805, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2017 --> Jun 2018 Trial primary completion date: Dec 2023 --> Dec 2016
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib (clinicaltrials.gov) - Apr 18, 2017
P, N=40, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Dec 2023 --> Dec 2016 Recruiting --> Active, not recruiting
- ||||| Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer (clinicaltrials.gov) - Apr 14, 2017
P3, N=418, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche, Actimmune (interferon gamma-1 b) / Clinigen, Amgen, Perjeta (pertuzumab) / Roche
New P1/2 trial: MCC-18936: Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer (clinicaltrials.gov) - Apr 13, 2017
P1/2, N=43, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- | Perjeta (pertuzumab) / Roche
New P1 trial: Imaging With a New Agent That Finds a Cancer Protein Called HER2 (clinicaltrials.gov) - Apr 12, 2017
P1, N=10, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: PERTAIN: A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (clinicaltrials.gov) - Apr 7, 2017
P2, N=258, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2019 --> May 2016 | Recruiting --> Active, not recruiting
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Apr 7, 2017
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Oct 2019 --> May 2016 | Recruiting --> Active, not recruiting Trial primary completion date: May 2017 --> Dec 2018
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Neurodex (dextromethorphan hydrobromide/quinidine sulfate) / Otsuka
Journal: Anti-Yo Mediated Paraneoplastic Cerebellar Degeneration Associated with Pseudobulbar Affect in a Patient with Breast Cancer. (Pubmed Central) - Apr 7, 2017
She was given IVIG for paraneoplastic syndrome, antidepressants, and dextromethorphan-quinidine (Nuedexta), the first FDA-approved therapy for PBA. With multimodality therapy, she demonstrated significant improvement in neurologic and mood symptoms associated with PCD and PBA.
- ||| Nerlynx (neratinib) / Puma, Perjeta (pertuzumab) / Roche
New P1 trial, Metastases: Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Apr 5, 2017
P1b, N=99, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: PATRICIA: A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy (clinicaltrials.gov) - Mar 23, 2017
P2, N=40, Recruiting, Sponsor: Genentech, Inc.
With multimodality therapy, she demonstrated significant improvement in neurologic and mood symptoms associated with PCD and PBA. Trial primary completion date: Dec 2018 --> Jun 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer (clinicaltrials.gov) - Mar 22, 2017
P2, N=88, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Dec 2018 --> Jun 2019 Trial primary completion date: Jan 2017 --> Sep 2017
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=135, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2017 --> Sep 2017 Trial primary completion date: Sep 2017 --> Dec 2020
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche
Enrollment status, Enrollment change, Trial primary completion date, Combination therapy: A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies (clinicaltrials.gov) - Mar 15, 2017
P2, N=720, Recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Sep 2017 --> Dec 2020 Enrolling by invitation --> Recruiting | N=500 --> 720 | Trial primary completion date: Sep 2022 --> Dec 2022
- || Enrollment change, Combination therapy: Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer (clinicaltrials.gov) - Mar 13, 2017
P1, N=100, Recruiting, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Recruiting | N=500 --> 720 | Trial primary completion date: Sep 2022 --> Dec 2022 N=66 --> 100